Abstract:Oligodendroglioma evolution is incompletely understood. Here we analyze serial oligodendroglioma samples to define genomic and cellular mechanisms underlying treatment resistance. RNA sequencing was performed on 53,406 spatial transcriptomes from 31 oligodendrogliomas (IDH mutant, 1p/19q-codeleted) that were resected from 16 patients. There were 15 CNS WHO grade 2 and 16 grade 3 oligodendrogliomas, which were stratified for temporal progression across grades (n=5 grade 2 to 2, n=5 grade 2 to 3, n=6 grade 3 to 3) and treatments between serial resections (n=2 TMZ/RT, n=2 TMZ, n=1 mTOR inhibition, n=1 IDH inhibition, n=10 surgical monotherapy). Spatial transcriptomic clusters were defined using cell signature gene sets, cell cycle analysis, differentially expressed marker genes, immunohistochemistry, spatial copy number alterations (CNAs), and deconvolution of 18,628 oligodendroglioma single-cell transcriptomes from 16 independent patients. Specificity was tested using immunofluorescence on independent oligodendrogliomas that did not recur after surgical monotherapy (n=8 samples, median follow-up 8.4 years) and spatial transcriptomic sequencing on 8 matched-paired astrocytomas from 4 patients. Integrated uniform manifold approximation and projection revealed a proneural/NPC-like cluster that was enriched in grade 3 oligodendroglioma samples and represented the starting point in oligodendroglioma lineage differentiation using RNA velocity, Monocle, and subclonal spatiotemporal CNA evolution. Comparison across treatment regimens showed (1) enrichment of the proneural/NPC-like cluster in recurrent versus primary tumors that were treated with surgical monotherapy, (2) enrichment of a proneural/OPC-like cluster and depletion of an oligodendrocyte-like cluster after TMZ/RT, (3) enrichment of proneural/NPC-like and immediate-early response clusters after TMZ/RT, (4) enrichment of the oligodendrocyte-like cluster following mTOR inhibition, and (5) enrichment of cancer associated fibroblasts (CAFs) following IDH inhibition. These data show the spatiotemporal landscape of oligodendroglioma is associated with branched lineage differentiation that is modified by postoperative therapy, and suggest that therapy-dependent druggable dependencies may exist to treat oligodendrogliomas that are resistant to standard interventions.

Path-36. Do Gene Expression Profiles Better Predict Oligodendroglioma Survival?

Quantitative Proteomic Analysis of Oligodendrogliomas with and Without 1p/19q Deletion

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes

Biom-30. Novel Histologic And Molecular Biomarkers For Oligodendroglioma

Identification of Differential Splicing Genes in Gliomas Using Exon Expression Profiling.

1237 The Mutational Landscape of Molecularly Defined Oligodendrogliomas

Oligodendroglioma patient survival is associated with circulating B-cells and age

Abstract 7564: DNA methylation profiling identifies two distinct groups of oligosarcoma, IDH-mutant with distinct genetic alterations and clinical outcomes

Gene Expression Patterns Associated with Survival in Glioblastoma

1P/19q-Driven Prognostic Molecular Classification for High-Grade Oligodendroglial Tumors

Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.

Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features

Genomic Alterations in Molecularly Defined Oligodendrogliomas

Bioinformatic Analysis Constructs an Optimal Prognostic Index for Survival-Related Variables (OPISV) Based on Whole-Genome Expression Data in Glioblastoma

Cnsc-52. Oligodendroglioma Spatial Transcriptomic Sequencing Reveals Therapy-Dependent Evolution Over Time

Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses

A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma

Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4,400 Tumors

Bioinformatic Analysis of Gene Expression and Methylation Regulation in Glioblastoma

Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods

Expression-based Intrinsic Glioma Subtypes Are Prognostic in Low-Grade Gliomas of the EORTC22033-26033 Clinical Trial.